Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation

Transplantation. 2004 Feb 27;77(4):587-96. doi: 10.1097/01.tp.0000111769.45088.a2.

Abstract

Background: Existing data indicate that non-human leukocyte antigen (HLA) immunogenetic polymorphisms influence the risk of complications after allogeneic hemopoietic stem-cell transplantation. However, prior studies have been limited by small sample size and limited genotyping.

Methods: We examined 22 polymorphisms in 11 immunoregulatory genes including cytokines, mediators of apoptosis, and host-defense molecules by polymerase chain reaction using sequence-specific primers in 160 related myeloablative transplants. Associations were confirmed in two independent cohorts.

Results: An intronic polymorphism in the tumor necrosis factor gene (TNF 488A) was associated with the risk of acute graft-versus-host disease (GVHD) (odds ratio [OR] 16.9), grades II to IV acute GVHD (OR 3.3), chronic GVHD (OR 12.5), and early death posttransplant (OR 3.4). Recipient Fas -670G and donor interleukin (IL)-6 -174G were independent risk factors for acute GVHD. Recipient IL-10 ATA and Fas -670 genotype were independent risk factors for chronic GVHD. Recipient IL-1beta +3953T was associated with hepatic acute GVHD, and Fas -670G was associated with major infection.

Conclusions: These results highlight the potential importance of cytokine and apoptosis gene polymorphisms in stem-cell transplantation, and indicate that non-HLA genotyping may be useful to identify individuals at the highest risk of complications and new targets for therapeutic intervention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Cells / transplantation
  • Bone Marrow Transplantation
  • Chronic Disease
  • Cohort Studies
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Genetic Predisposition to Disease*
  • Graft vs Host Disease / genetics*
  • Graft vs Host Disease / prevention & control
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interleukins / genetics*
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Polymorphism, Genetic*
  • Transplantation, Homologous / adverse effects
  • Tumor Necrosis Factor-alpha / genetics*
  • fas Receptor / genetics*

Substances

  • Immunosuppressive Agents
  • Interleukins
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • Cyclosporine
  • Methotrexate